Company Filing History:
Years Active: 2001
Title: Innovations of Markus Grütter in Crystalline Formulations
Introduction
Markus Grütter is an accomplished inventor based in Hochwald, Switzerland. He has made significant contributions to the field of pharmaceutical formulations, particularly in the area of transforming growth factor beta (TGF-β) crystals. His innovative work has implications for drug design and stability.
Latest Patents
Grütter holds a patent for "Transforming growth factor β crystals." This invention concerns TGF-β in a crystalline form that exhibits reduced adsorption to vial walls compared to its soluted counterpart. Additionally, the crystalline form demonstrates greater stability against oxidative agents. The TGF-β crystals developed by Grütter can be utilized for structure determination, drug design, and the production of slow-release pharmaceutical preparations. He has 1 patent to his name.
Career Highlights
Grütter is associated with Novartis Corporation, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in drug formulation and delivery systems. His expertise in crystallization techniques has positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Throughout his career, Grütter has collaborated with notable colleagues, including Peer Mittl and Tudor Arvinte. These collaborations have fostered a productive environment for research and development, leading to advancements in pharmaceutical technologies.
Conclusion
Markus Grütter's contributions to the field of pharmaceutical formulations, particularly through his patent on TGF-β crystals, highlight his innovative spirit and dedication to improving drug stability and delivery. His work continues to influence the pharmaceutical industry positively.